

PFIZER IS MOVING THROUGH A CYCLE OF RENEWAL.

WE'VE BUILT THE INDUSTRY'S MOST-PROMISING
PIPELINE OF NEW PHARMACEUTICALS.

WE'RE LAUNCHING NOVEL MEDICINES TAKING
AIM AT FEARED DISEASES.

WE'RE EXPLORING NEW DIRECTIONS IN
KEEPING HEALTHCARE PERSONAL, AFFORDABLE
AND ACCESSIBLE.

OUR CHALLENGE:

[BUILD THE NEXT-GENERATION PFIZER.](#)

**[WE HAVE THE TEAM, THE STRENGTH AND
THE WILL TO DO IT.](#)**



INTRODUCTION	1
NEW HOPE FOR PATIENTS	2
CHAIRMAN'S LETTER TO SHAREHOLDERS	8
FINANCIAL HIGHLIGHTS	12
DELIVER MORE NEW MEDICINES, MORE QUICKLY, TO PATIENTS	14
DRIVE OUR ADVANTAGES IN SIZE, REACH AND PRODUCTIVITY	23
BUILD THE PERFORMANCE POTENTIAL OF EACH COLLEAGUE	26
SHAPE A POSITIVE ENVIRONMENT FOR BETTER HEALTHCARE	29
CREATE NEW DIRECTIONS IN HEALTH AND WELLNESS	32
BOARD OF DIRECTORS	36
CORPORATE AND SHAREHOLDER INFORMATION	INSIDE BACK COVER

THE NEXT-GENERATION PFIZER

- KEEP THE FOCUS ON PATIENTS
- TRANSFORM OUR COMPANY
- DELIVER NEW VALUE

The cycle of renewal drives everything we do at Pfizer. With several Pfizer medicines now coming to the end of their life cycles, we are doing what Pfizer people have done many times since our founding in 1849—build a new platform for extended growth. Pfizer colleagues around the world are putting into place the next-generation Pfizer, one that will meet fast-changing needs in health and healthcare.

We are working hard to both transform our business and to be partners in transforming healthcare itself. Our focus remains on our core business—innovation in the medicines that are integral to good healthcare. But our strategy goes further—to help create entire new directions in health and healthcare, exploring systems that start with the simple question: “How can we best help people

Our plans to transform Pfizer capitalize on every one of our strengths—our size, global reach, knowledge of health and disease, and unmatched resources in biomedical R&D. Central to our transformation is a new generation of Pfizer medicines either recently launched or planned for launch. In 2005, we introduced four new medicines in the United States. In 2006, we have plans to launch six new medicines in the U.S.—three of which are already approved by the FDA. What follows are some highlights of a new wave of medicines offering new hope for patients, new value for investors and new growth for Pfizer.



"You have provided reason for hope. Sutant and Pfizer have allowed me to not only survive, but also to live a normal life."


JULIA BARCHITTA, SUTENT PATIENT WITH HER SON, JOHN

SUTENT

FIRST OF A NEW WAVE OF CANCER MEDICINES

Sutant brings new hope to patients suffering from cancers once thought hopeless—specifically, metastatic renal cell carcinomas and gastrointestinal stromal tumors that have become resistant to standard treatments. Taken orally, Sutant both decreases the rate at which cancer cells proliferate and causes these cells to die while

feed tumors. Sutant was approved by the FDA in January 2006 and was available to patients in the U.S. within seven days of its approval. It was one of the fastest approvals on record. Sutant demonstrates Pfizer's growing presence in oncology and is the first of a new wave of medicines



"I've been taking injections for over 21 years. After all this time it still bothers me. Exubera offers me new freedoms, a new lease on life."

RICHARD St. PIERRE, EXUBERA PATIENT

EXUBERA

THE WORLD'S FIRST INHALED INSULIN

Exubera is the first new method of delivering human insulin in more than 80 years. Developed in conjunction with Nektar Therapeutics, Exubera is a powdered form of insulin, inhaled through the use of a novel, compact, canister-shaped device the size of an eyeglass case.

This therapy takes aim at a growing global epidemic with terrible consequences—heart disease, blindness and circulation problems leading to amputations. Exubera's greatest contribution may be to patients failing on oral diabetes agents and delaying further treatment of this devastating disease.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.